Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper

go back to reference Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, Allison M, Hemingway H, Cleland JG, McMurray JJV, Rahimi K (2018) Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet 391:572–580CrossRef Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, Allison M, Hemingway H, Cleland JG, McMurray JJV, Rahimi K (2018) Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet 391:572–580CrossRef

go back to reference Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF, de Boer RA, Drexel H, Ben Gal T, Hill L, Jaarsma T, Jankowska EA, Anker MS, Lainscak M, Lewis BS, McDonagh T, Metra M, Milicic D, Mullens W, Piepoli MF, Rosano G, Ruschitzka F, Volterrani M, Voors AA, Filippatos G, Coats AJS (2019) Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of The Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 21:1169–1186CrossRef Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF, de Boer RA, Drexel H, Ben Gal T, Hill L, Jaarsma T, Jankowska EA, Anker MS, Lainscak M, Lewis BS, McDonagh T, Metra M, Milicic D, Mullens W, Piepoli MF, Rosano G, Ruschitzka F, Volterrani M, Voors AA, Filippatos G, Coats AJS (2019) Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of The Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 21:1169–1186CrossRef

go back to reference Filippatos G, Farmakis D, Bistola V, Karavidas A, Mebazaa A, Maggioni AP, Parissis J (2014) Temporal trends in epidemiology, clinical presentation and management of acute heart failure: results from the Greek cohorts of the Acute Heart Failure Global Registry of Standard Treatment and the European Society of Cardiology Heart Failure pilot survey. Eur Heart J Acute Cardiovasc Care. https://doi.org/10.1177/2048872614527012CrossRefPubMed Filippatos G, Farmakis D, Bistola V, Karavidas A, Mebazaa A, Maggioni AP, Parissis J (2014) Temporal trends in epidemiology, clinical presentation and management of acute heart failure: results from the Greek cohorts of the Acute Heart Failure Global Registry of Standard Treatment and the European Society of Cardiology Heart Failure pilot survey. Eur Heart J Acute Cardiovasc Care. https://​doi.​org/​10.​1177/​2048872614527012​CrossRefPubMed

go back to reference Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Fabbri G, Urso R, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors AA, Nielsen OW, Zannad F, Tavazzi L (2013) EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Heart Failure Association of the European Society of Cardiology (HFA). Eur J Heart Fail 15:808–817CrossRef Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Fabbri G, Urso R, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors AA, Nielsen OW, Zannad F, Tavazzi L (2013) EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Heart Failure Association of the European Society of Cardiology (HFA). Eur J Heart Fail 15:808–817CrossRef

go back to reference Hollenberg SM, Stevenson LW, Ahmad T, Amin VJ, Bozkurt B, Butler J, Davies L, Drazner MH, Kirkpatrick JN, Peterson PN, Reed BN, Roy CL, Storrow AB (2019) 2019 ACC Expert Consensus Decision Pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure. J Am Coll Cardiol 74:1966–2011CrossRef Hollenberg SM, Stevenson LW, Ahmad T, Amin VJ, Bozkurt B, Butler J, Davies L, Drazner MH, Kirkpatrick JN, Peterson PN, Reed BN, Roy CL, Storrow AB (2019) 2019 ACC Expert Consensus Decision Pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure. J Am Coll Cardiol 74:1966–2011CrossRef

go back to reference Sanam K, Bhatia V, Bajaj NS, Gaba S, Morgan CJ, Fonarow GC, Butler J, Deedwania P, Prabhu SD, Wu WC, White M, Love TE, Aronow WS, Fletcher RD, Allman RM, Ahmed A (2016) Renin-angiotensin system inhibition and lower 30-day all-cause readmission in Medicare Beneficiaries with heart failure. Am J Med 129(10):1067–1073CrossRef Sanam K, Bhatia V, Bajaj NS, Gaba S, Morgan CJ, Fonarow GC, Butler J, Deedwania P, Prabhu SD, Wu WC, White M, Love TE, Aronow WS, Fletcher RD, Allman RM, Ahmed A (2016) Renin-angiotensin system inhibition and lower 30-day all-cause readmission in Medicare Beneficiaries with heart failure. Am J Med 129(10):1067–1073CrossRef

go back to reference Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O’Connor CM, Sun JL, Yancy C, Young JB (2007) Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 153:82e1-e11CrossRef Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O’Connor CM, Sun JL, Yancy C, Young JB (2007) Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 153:82e1-e11CrossRef

go back to reference Jondeau G, Neuder Y, Eicher JC, Jourdain P, Fauveau E, Galinier M, Jegou A, Bauer F, Trochu JN, Bouzamondo A, Tanguy ML, Lechat P (2009) B-CONVINCED: beta-blocker CONtinuation Vs. interruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J 30:2186–2192CrossRef Jondeau G, Neuder Y, Eicher JC, Jourdain P, Fauveau E, Galinier M, Jegou A, Bauer F, Trochu JN, Bouzamondo A, Tanguy ML, Lechat P (2009) B-CONVINCED: beta-blocker CONtinuation Vs. interruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J 30:2186–2192CrossRef

go back to reference Bistola V, Simitsis P, Farmakis D, Ikonomidis I, Bakosis G, Triposkiadis F, Hatziagelaki E, Lekakis J, Mebazaa A, Parissis J (2018) Association of mineralocorticoid receptor antagonist use and in-hospital outcomes in patients with acute heart failure. Clin Res Cardiol 107:76–86CrossRef Bistola V, Simitsis P, Farmakis D, Ikonomidis I, Bakosis G, Triposkiadis F, Hatziagelaki E, Lekakis J, Mebazaa A, Parissis J (2018) Association of mineralocorticoid receptor antagonist use and in-hospital outcomes in patients with acute heart failure. Clin Res Cardiol 107:76–86CrossRef

go back to reference Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Group ESCSD (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129–2200CrossRef Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Group ESCSD (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129–2200CrossRef

go back to reference Yancy CW, Jessup M, Bozkurt B et al (2017) 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136(6):e137–e161CrossRef Yancy CW, Jessup M, Bozkurt B et al (2017) 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136(6):e137–e161CrossRef

go back to reference Kozhuharov N, Goudev A, Flores D, Maeder MT, Walter J, Shrestha S, Gualandro DM, de Oliveira MT Jr, Sabti Z, Müller B, Noveanu M, Socrates T, Ziller R, Bayés-Genís A, Sionis A, Simon P, Michou E, Gujer S, Gori T, Wenzel P, Pfister O, Conen D, Kapos I, Kobza R, Rickli H, Breidthardt T, Münzel T, Erne P, Mueller C, GALACTIC Investigators, Mueller C, Erne P, Müller B, Rickli H, Maeder M, de Oliveira MT Jr, Bayés-Genís A, Sionis A, Goudev A, Dimov B, Hartwiger S, Arenja N, Glatz B, Herr N, Isenrich R, Mosimann T, Twerenbold R, Boeddinghaus J, Nestelberger T, Puelacher C, Freese M, Vögele J, Meissner K, Martin J, Strebel I, Wussler D, Schumacher C, Osswald S, Vogt F, Hilti J, Barata S, Schneider D, Schwarz J, Fitze B, Hartwiger S, Arenja N, Glatz B, Herr N, Isenrich R, Mosimann T, Rentsch K, Bossa A, Jallad S, Soeiro A, Georgiev D, Jansen T, Gebel G, Bossard M, Christ M (2019) Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Failure: The GALACTIC Randomized Clinical Trial. JAMA 322(23):2292–2302CrossRef Kozhuharov N, Goudev A, Flores D, Maeder MT, Walter J, Shrestha S, Gualandro DM, de Oliveira MT Jr, Sabti Z, Müller B, Noveanu M, Socrates T, Ziller R, Bayés-Genís A, Sionis A, Simon P, Michou E, Gujer S, Gori T, Wenzel P, Pfister O, Conen D, Kapos I, Kobza R, Rickli H, Breidthardt T, Münzel T, Erne P, Mueller C, GALACTIC Investigators, Mueller C, Erne P, Müller B, Rickli H, Maeder M, de Oliveira MT Jr, Bayés-Genís A, Sionis A, Goudev A, Dimov B, Hartwiger S, Arenja N, Glatz B, Herr N, Isenrich R, Mosimann T, Twerenbold R, Boeddinghaus J, Nestelberger T, Puelacher C, Freese M, Vögele J, Meissner K, Martin J, Strebel I, Wussler D, Schumacher C, Osswald S, Vogt F, Hilti J, Barata S, Schneider D, Schwarz J, Fitze B, Hartwiger S, Arenja N, Glatz B, Herr N, Isenrich R, Mosimann T, Rentsch K, Bossa A, Jallad S, Soeiro A, Georgiev D, Jansen T, Gebel G, Bossard M, Christ M (2019) Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Failure: The GALACTIC Randomized Clinical Trial. JAMA 322(23):2292–2302CrossRef

go back to reference Rosenblum H, Kapur N, Abraham W, Udelson J, Itkin M, Uriel N, Voors A, Burkhoff D (2020) Conceptual Considerations for Device-Based Therapy in Acute Decompensated Heart Failure: DRI 2 P 2 S. Circ Heart Fail 13(4):e006731. https://doi.org/10.1161/CIRCHEARTFAILURE.119.006731 (Epub 2020 Apr 16)CrossRefPubMed Rosenblum H, Kapur N, Abraham W, Udelson J, Itkin M, Uriel N, Voors A, Burkhoff D (2020) Conceptual Considerations for Device-Based Therapy in Acute Decompensated Heart Failure: DRI 2 P 2 S. Circ Heart Fail 13(4):e006731. https://​doi.​org/​10.​1161/​CIRCHEARTFAILURE​.​119.​006731 (Epub 2020 Apr 16)CrossRefPubMed

go back to reference Velazquez EJ, Morrow DA, DeVore AD, Duffy C, Ambrosy A, McCague K, Rocha R, Braunwald E, Investigators PIONEER-HF (2019) Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 380(6):539–548CrossRef Velazquez EJ, Morrow DA, DeVore AD, Duffy C, Ambrosy A, McCague K, Rocha R, Braunwald E, Investigators PIONEER-HF (2019) Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 380(6):539–548CrossRef

go back to reference Bhagat A, Greene S, Vaduganathan M, Fonarow G, Butler J (2019) Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. JACC Heart Fail 7(1):1–12. https://doi.org/10.1016/j.jchf.2018.06.011CrossRefPubMed Bhagat A, Greene S, Vaduganathan M, Fonarow G, Butler J (2019) Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. JACC Heart Fail 7(1):1–12. https://​doi.​org/​10.​1016/​j.​jchf.​2018.​06.​011CrossRefPubMed

go back to reference Allen L, Fonarow G, Liang L, Schulte P, Masoudi F, Rumsfeld J, Ho M, Eapen Z, Hernandez A, Heidenreich P, Bhatt D, Peterson E, Krumholz H, on behalf of the American Heart Association’s Get With The Guidelines Heart Failure (GWTG-HF) Investigators (2015) Medication Initiation Burden Required to Comply with Heart Failure Guideline Recommendations and Hospital Quality Measures. Circulation 132(14):1347–1353CrossRef Allen L, Fonarow G, Liang L, Schulte P, Masoudi F, Rumsfeld J, Ho M, Eapen Z, Hernandez A, Heidenreich P, Bhatt D, Peterson E, Krumholz H, on behalf of the American Heart Association’s Get With The Guidelines Heart Failure (GWTG-HF) Investigators (2015) Medication Initiation Burden Required to Comply with Heart Failure Guideline Recommendations and Hospital Quality Measures. Circulation 132(14):1347–1353CrossRef

go back to reference Farmakis D, Parissis J, Karavidas A, Karvounis C, Triposkiadis F, Filippatos G, Lekakis J (2015) In-hospital management of acute heart failure: Practical recommendations and future perspectives. Int J Cardiol 201:231–236CrossRef Farmakis D, Parissis J, Karavidas A, Karvounis C, Triposkiadis F, Filippatos G, Lekakis J (2015) In-hospital management of acute heart failure: Practical recommendations and future perspectives. Int J Cardiol 201:231–236CrossRef

go back to reference Arvanitaki A, Michou E, Kalogeropoulos A, Karvounis H, Giannakoulas G (2020) Mildly symptomatic heart failure with reduced ejection fraction: diagnostic and therapeutic considerations. ESC Heart Fail 7(4):1477–1487CrossRef Arvanitaki A, Michou E, Kalogeropoulos A, Karvounis H, Giannakoulas G (2020) Mildly symptomatic heart failure with reduced ejection fraction: diagnostic and therapeutic considerations. ESC Heart Fail 7(4):1477–1487CrossRef

go back to reference McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, Investigators Committees PH (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993–1004CrossRef McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, Investigators Committees PH (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993–1004CrossRef

go back to reference Desai AS, Solomon SD, Shah AM, Claggett B, Fang J, Izzo J, McCague K, Abbas C, Rocha R, Mitchell G (2019) Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial [published online ahead of print, 2019 Sep 2]. JAMA 322(11):1–10 Desai AS, Solomon SD, Shah AM, Claggett B, Fang J, Izzo J, McCague K, Abbas C, Rocha R, Mitchell G (2019) Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial [published online ahead of print, 2019 Sep 2]. JAMA 322(11):1–10

go back to reference D’Elia E, Iacovoni A, Vaduganathan M, Lorini FL, Perlini S, Senni M (2017) Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. Eur J Heart Failure 19:710–717CrossRef D’Elia E, Iacovoni A, Vaduganathan M, Lorini FL, Perlini S, Senni M (2017) Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. Eur J Heart Failure 19:710–717CrossRef

go back to reference Zile MR, O’Meara E, Claggett B, Prescott M, Solomon S, Swedberg K, Packer M, McMurray J, Shi V, Lefkowitz M, Rouleay J (2019) Effects of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF. J Am Coll Cardiol 73(7):795–806CrossRef Zile MR, O’Meara E, Claggett B, Prescott M, Solomon S, Swedberg K, Packer M, McMurray J, Shi V, Lefkowitz M, Rouleay J (2019) Effects of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF. J Am Coll Cardiol 73(7):795–806CrossRef

go back to reference Januzzi JL Jr, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, Camacho A, Piña IL, Rocha RA, Shah AM, Williamson KM, Solomon SD, Investigators PROVE-HF (2019) Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA 322(11):1–11. https://doi.org/10.1001/jama.2019.12821CrossRef Januzzi JL Jr, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, Camacho A, Piña IL, Rocha RA, Shah AM, Williamson KM, Solomon SD, Investigators PROVE-HF (2019) Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA 322(11):1–11. https://​doi.​org/​10.​1001/​jama.​2019.​12821CrossRef

go back to reference Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, Prescott MF, Shi VC, Rouleau JL, Swedberg K, Zile MR, Packer M, Desai AS, Solomon SD, McMurray JJV (2018) Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail 6(6):489–498CrossRef Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, Prescott MF, Shi VC, Rouleau JL, Swedberg K, Zile MR, Packer M, Desai AS, Solomon SD, McMurray JJV (2018) Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail 6(6):489–498CrossRef

go back to reference Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, Rouleau JL, Swedberg K, Lefkowitz M, Shi VC, Desai AS, McMurray JJV, Solomon SD (2017) Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol 5(5):333–340CrossRef Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, Rouleau JL, Swedberg K, Lefkowitz M, Shi VC, Desai AS, McMurray JJV, Solomon SD (2017) Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol 5(5):333–340CrossRef

go back to reference Desai AS, Vardeny O, Claggett B, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Zile MR, Lefkowitz M, Shi V, Solomon SD (2017) Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF Trial. JAMA Cardiol 2(1):79–85CrossRef Desai AS, Vardeny O, Claggett B, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Zile MR, Lefkowitz M, Shi V, Solomon SD (2017) Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF Trial. JAMA Cardiol 2(1):79–85CrossRef

go back to reference Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Butler J, Davis LL, Fonarow GC, Ibrahim NE, Lindenfeld J, Masoudi FA, Motiwala SR, Oliveros E, Patterson JH, Walsh MN, Wasserman A, Yancy CW, Youmans QR (2021) 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 77(6):772–810CrossRef Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Butler J, Davis LL, Fonarow GC, Ibrahim NE, Lindenfeld J, Masoudi FA, Motiwala SR, Oliveros E, Patterson JH, Walsh MN, Wasserman A, Yancy CW, Youmans QR (2021) 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 77(6):772–810CrossRef

go back to reference Mann DL, Greene SJ, Givertz MM, Vader JM, Starling RC, Ambrosy AP, Shah P, McNulty SE, Mahr C, Gupta D, Redfield MM, Lala A, Lewis GD, Mohammed SF, Gilotra NA, DeVore A, Gorodeski EZ, Desvigne-Nickens P, Hernandez AF, Braunwald E (2020) Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. JACC Heart Fail 8(10):789–799CrossRef Mann DL, Greene SJ, Givertz MM, Vader JM, Starling RC, Ambrosy AP, Shah P, McNulty SE, Mahr C, Gupta D, Redfield MM, Lala A, Lewis GD, Mohammed SF, Gilotra NA, DeVore A, Gorodeski EZ, Desvigne-Nickens P, Hernandez AF, Braunwald E (2020) Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. JACC Heart Fail 8(10):789–799CrossRef

go back to reference Wachter R, Senni M, Belohlavek J, Straburzynska-Migaj E, Witte KK, Kobalava Z, Fonseca C, Goncalvesova E, Cavusoglu Y, Fernandez A, Chaaban S, Bøhmer E, Pouleur AC, Mueller C, Tribouilloy C, Lonn E, A L Buraiki J, Gniot J, Mozheiko M, Lelonek M, Noè A, Schwende H, Bao W, Butylin D, Pascual-Figal D; TRANSITION Investigators. (2019) Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail 21(8):998–1007CrossRef Wachter R, Senni M, Belohlavek J, Straburzynska-Migaj E, Witte KK, Kobalava Z, Fonseca C, Goncalvesova E, Cavusoglu Y, Fernandez A, Chaaban S, Bøhmer E, Pouleur AC, Mueller C, Tribouilloy C, Lonn E, A L Buraiki J, Gniot J, Mozheiko M, Lelonek M, Noè A, Schwende H, Bao W, Butylin D, Pascual-Figal D; TRANSITION Investigators. (2019) Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail 21(8):998–1007CrossRef

go back to reference Senni M, Wachter R, Witte K, Straburzynska-Migaj E, Belohlavek J, C, Mueller C, Lonn E, Chakrabarti A, Bao W, Noe A, Schwende H, Butylin D, Pascual-Figal D, TRANSITION Investigators. (2020) Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study. Eur J Heart Fail 22(2):303–312CrossRef Senni M, Wachter R, Witte K, Straburzynska-Migaj E, Belohlavek J, C, Mueller C, Lonn E, Chakrabarti A, Bao W, Noe A, Schwende H, Butylin D, Pascual-Figal D, TRANSITION Investigators. (2020) Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study. Eur J Heart Fail 22(2):303–312CrossRef

go back to reference Pascual-Figal D, Wachter R, Senni M, Bao W, Noe A, Schwende H, Butylin D, Prescott M (2020) NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study. JACC Heart Fail S2213–1779(20)30336-X Pascual-Figal D, Wachter R, Senni M, Bao W, Noe A, Schwende H, Butylin D, Prescott M (2020) NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study. JACC Heart Fail S2213–1779(20)30336-X

go back to reference Ambrosy AP, DeVore AD, Velazquez EJ (2019) In-hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time. Eur J Heart Fail 21(8):1008–1011CrossRef Ambrosy AP, DeVore AD, Velazquez EJ (2019) In-hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time. Eur J Heart Fail 21(8):1008–1011CrossRef

go back to reference Morrow DA, Velazquez EJ, DeVore AD, Prescott M, Duffy C, Gurmu Y, McCague K, Rocha R, Braunwald E (2019) Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. Eur Heart J 40(40):3345–3352CrossRef Morrow DA, Velazquez EJ, DeVore AD, Prescott M, Duffy C, Gurmu Y, McCague K, Rocha R, Braunwald E (2019) Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. Eur Heart J 40(40):3345–3352CrossRef

go back to reference Morrow DA, Velazquez EJ, DeVore AD, Desai AS, Duffy CI, Ambrosy AP, Gurmu Y, McCague K, Rocha R, Braunwald E (2019) Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. Circulation 139(19):2285–2288CrossRef Morrow DA, Velazquez EJ, DeVore AD, Desai AS, Duffy CI, Ambrosy AP, Gurmu Y, McCague K, Rocha R, Braunwald E (2019) Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. Circulation 139(19):2285–2288CrossRef

go back to reference Berg DD, Braunwald E, DeVore AD, Lala A, Pinney SP, Duffy CI, Gurmu Y, Velazquez EJ, Morrow DA (2020) Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. JACC Heart Fail S2213–1779(20)30384-X Berg DD, Braunwald E, DeVore AD, Lala A, Pinney SP, Duffy CI, Gurmu Y, Velazquez EJ, Morrow DA (2020) Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. JACC Heart Fail S2213–1779(20)30384-X

go back to reference Ambrosy AP, Braunwald E, Morrow DA, De Vore A, McCague K, Meng X, Duffy C, Rocha R, Velazquez E (2020) Angiotensin receptor-neprilysin inhibition based on history of heart failure and use of renin-angiotensin system antagonists. J Am Coll Cardiol 76(9):1034–1048CrossRef Ambrosy AP, Braunwald E, Morrow DA, De Vore A, McCague K, Meng X, Duffy C, Rocha R, Velazquez E (2020) Angiotensin receptor-neprilysin inhibition based on history of heart failure and use of renin-angiotensin system antagonists. J Am Coll Cardiol 76(9):1034–1048CrossRef

go back to reference DeVore AD, Braunwald E, Morrow DA, Duffy C, Ambrosy A, Chakraborty H, McCague K, Rocha R, Velazquez E (2019) Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial [published online ahead of print, Dec 11]. JAMA Cardiol 5(2):202–207 DeVore AD, Braunwald E, Morrow DA, Duffy C, Ambrosy A, Chakraborty H, McCague K, Rocha R, Velazquez E (2019) Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial [published online ahead of print, Dec 11]. JAMA Cardiol 5(2):202–207

go back to reference Gaziano TA, Fonarow GC, Velazquez EJ, Morrow DA, Braunwald E, Solomon SD (2020) Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction. JAMA Cardiol 5(11):1236–1244 Gaziano TA, Fonarow GC, Velazquez EJ, Morrow DA, Braunwald E, Solomon SD (2020) Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction. JAMA Cardiol 5(11):1236–1244

go back to reference Greene SJ, Triana TS, Ionescu-Ittu R, Burne R, Guerin A, Borentain M, Kessler P, Tugsu A, DeSouza M, Felker M, Chen L. (2020) In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States [published online ahead of print, Aug 12]. JACC Heart Fail S2213–1779(20)30383–8 Greene SJ, Triana TS, Ionescu-Ittu R, Burne R, Guerin A, Borentain M, Kessler P, Tugsu A, DeSouza M, Felker M, Chen L. (2020) In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States [published online ahead of print, Aug 12]. JACC Heart Fail S2213–1779(20)30383–8

go back to reference Srivastava P, Fonarow G (2019) In-Hospital Initiation of Angiotensin Receptor-Neprilysin Inhibitors-The Time Is Now. JAMA Cardiol 4(3):195–196. https://doi.org/10.1001/jamacardio.2019.0104CrossRefPubMed Srivastava P, Fonarow G (2019) In-Hospital Initiation of Angiotensin Receptor-Neprilysin Inhibitors-The Time Is Now. JAMA Cardiol 4(3):195–196. https://​doi.​org/​10.​1001/​jamacardio.​2019.​0104CrossRefPubMed

go back to reference Fudim M, Sayeed S, Xu H, Matsouaka RA, Heidenreich PA, Velazquez EJ, Yancy CW, Fonarow GC, Hernandez AF, DeVore AD (2020) Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction. Circ Heart Fail 13(4):e006645CrossRef Fudim M, Sayeed S, Xu H, Matsouaka RA, Heidenreich PA, Velazquez EJ, Yancy CW, Fonarow GC, Hernandez AF, DeVore AD (2020) Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction. Circ Heart Fail 13(4):e006645CrossRef

go back to reference Chioncel O, Mebazaa A, Maggioni AP, Harjola VP, Rosano G, Laroche C, Piepoli M, Crespo-Leiro M, Lainscak M, Ponikowski P, Fillipatos G, Ruschitzka F, Seferovic P, Coats A, Lund L (2019) Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail 21(11):1338–1352. https://doi.org/10.1002/ejhf.1492CrossRefPubMed Chioncel O, Mebazaa A, Maggioni AP, Harjola VP, Rosano G, Laroche C, Piepoli M, Crespo-Leiro M, Lainscak M, Ponikowski P, Fillipatos G, Ruschitzka F, Seferovic P, Coats A, Lund L (2019) Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail 21(11):1338–1352. https://​doi.​org/​10.​1002/​ejhf.​1492CrossRefPubMed

go back to reference Antoniou CK, Chrysohoou C, Lerakis S, Manolakou P, Pitsavos C, Tsioufis K, Stefanadis C, Tousoulis D (2015) Effects of ventriculoarterial coupling changes on renal function, echocardiographic indices and energy efficiency in patients with acute decompensated systolic heart failure under furosemide and dopamine treatment: a comparison of three therapeutic protocols. Int J Cardiol 199:44–49CrossRef Antoniou CK, Chrysohoou C, Lerakis S, Manolakou P, Pitsavos C, Tsioufis K, Stefanadis C, Tousoulis D (2015) Effects of ventriculoarterial coupling changes on renal function, echocardiographic indices and energy efficiency in patients with acute decompensated systolic heart failure under furosemide and dopamine treatment: a comparison of three therapeutic protocols. Int J Cardiol 199:44–49CrossRef

go back to reference Triposkiadis FK, Butler J, Karayannis G, Starling R, Fillipatos G, Wolski K, Parissis J, Parisis C, Rovithis D, Koutrakis K, Skoularigis J, Antoniou CK, Chrysohoou C, Pitsavos C, Stefanadis C, Nastas J, Tsaknakis T, Mantziari L, Giannakoulas G, Karvounis H, Kalogeropoulos A, Giamouzis G (2014) Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial. Int J Cardiol 172(1):115–121CrossRef Triposkiadis FK, Butler J, Karayannis G, Starling R, Fillipatos G, Wolski K, Parissis J, Parisis C, Rovithis D, Koutrakis K, Skoularigis J, Antoniou CK, Chrysohoou C, Pitsavos C, Stefanadis C, Nastas J, Tsaknakis T, Mantziari L, Giannakoulas G, Karvounis H, Kalogeropoulos A, Giamouzis G (2014) Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial. Int J Cardiol 172(1):115–121CrossRef

go back to reference Javaloyes P, Miró Ò, Gil V, Martin-Sanchez FJ, Jacob J, Herrero P, Takagi K, Alquezar-Arbe A, Lopez Diez MP, Martin E, Bibiano C, Escoda R, Gil C, Fuentes M, Llopis Garcia G, Alvarez Perez JM, Jerez A, Tost J, Llauger L, Romero R, Garido JM, Rodriguez-Adrada E, Sanchez C, Rossello X, Parissis J, Mebazza A, Chioncel O, Llorens P (2019) Clinical phenotypes of acute heart failure based on signs and symptoms of perfusion and congestion at emergency department presentation and their relationship with patient management and outcomes. Eur J Heart Fail 21(11):1353–1365CrossRef Javaloyes P, Miró Ò, Gil V, Martin-Sanchez FJ, Jacob J, Herrero P, Takagi K, Alquezar-Arbe A, Lopez Diez MP, Martin E, Bibiano C, Escoda R, Gil C, Fuentes M, Llopis Garcia G, Alvarez Perez JM, Jerez A, Tost J, Llauger L, Romero R, Garido JM, Rodriguez-Adrada E, Sanchez C, Rossello X, Parissis J, Mebazza A, Chioncel O, Llorens P (2019) Clinical phenotypes of acute heart failure based on signs and symptoms of perfusion and congestion at emergency department presentation and their relationship with patient management and outcomes. Eur J Heart Fail 21(11):1353–1365CrossRef

go back to reference Ochiai ME, Brancalhão EC, Puig RS, Vieira KR, Cardoso JN, Oliveira MT Jr, Barretto AC (2014) Short-term add-on therapy with angiotensin receptor blocker for end-stage inotrope-dependent heart failure patients: B-type natriuretic peptide reduction in a randomized clinical trial. Clinics (Sao Paulo) 69(5):308–313CrossRef Ochiai ME, Brancalhão EC, Puig RS, Vieira KR, Cardoso JN, Oliveira MT Jr, Barretto AC (2014) Short-term add-on therapy with angiotensin receptor blocker for end-stage inotrope-dependent heart failure patients: B-type natriuretic peptide reduction in a randomized clinical trial. Clinics (Sao Paulo) 69(5):308–313CrossRef

go back to reference Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, Jeffrey Testani J, Tang W, Orso F, Rossignol P, Metra M, Filippatos G, Seferovic P, Ruschitzka F, Coats A (2019) The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 21(2):137–155. https://doi.org/10.1002/ejhf.1369 (Epub 2019 Jan 1)CrossRefPubMed Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, Jeffrey Testani J, Tang W, Orso F, Rossignol P, Metra M, Filippatos G, Seferovic P, Ruschitzka F, Coats A (2019) The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 21(2):137–155. https://​doi.​org/​10.​1002/​ejhf.​1369 (Epub 2019 Jan 1)CrossRefPubMed

go back to reference Lancellotti P, Galderisi M, Edvardsen T, Donal E, Goliasch G, Cardim N, Magne J, Laginha S, Hagendorff A, Haland TF, Aaberge L, Martinez C, Rapacciuolo A, Santoro C, Ilardi F, Postolache A, Dulgheru R, Mateescu AD, Beladan CC, Deleanu D, Marchetta S, Auffret V, Schwammenthal E, Habib G, Popescu BA (2017) Echo Doppler estimation of left ventricular filling pressure: results of the multicentre EACVI Euro-Filling study. Eur Heart J Cardiovasc Imaging 18(9):961–968CrossRef Lancellotti P, Galderisi M, Edvardsen T, Donal E, Goliasch G, Cardim N, Magne J, Laginha S, Hagendorff A, Haland TF, Aaberge L, Martinez C, Rapacciuolo A, Santoro C, Ilardi F, Postolache A, Dulgheru R, Mateescu AD, Beladan CC, Deleanu D, Marchetta S, Auffret V, Schwammenthal E, Habib G, Popescu BA (2017) Echo Doppler estimation of left ventricular filling pressure: results of the multicentre EACVI Euro-Filling study. Eur Heart J Cardiovasc Imaging 18(9):961–968CrossRef

go back to reference McCallum W, Tighiouart H, Testani J, Griffin M, Konstam M, Udelson J, Sarnak M (2020) Acute kidney function declines in the context of decongestion in acute decompensated heart failure. JACC Heart Fail 8(7):537–547CrossRef McCallum W, Tighiouart H, Testani J, Griffin M, Konstam M, Udelson J, Sarnak M (2020) Acute kidney function declines in the context of decongestion in acute decompensated heart failure. JACC Heart Fail 8(7):537–547CrossRef

go back to reference Guarracino F, Zima E, Pollesello P, Masip J (2020) Short term treatments for acute cardiac care: inotropes and inodilators. Eur Heart J Suppl 22(Suppl D):D3-D11 Guarracino F, Zima E, Pollesello P, Masip J (2020) Short term treatments for acute cardiac care: inotropes and inodilators. Eur Heart J Suppl 22(Suppl D):D3-D11

go back to reference Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM (2020) Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol 75(10):1178–1195CrossRef Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM (2020) Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol 75(10):1178–1195CrossRef

go back to reference Stevenson LW (2003) Clinical Use of Inotropic Therapy for Heart Failure: Looking Backward or Forward? Part I: Inotropic Infusions During Hospitalization. Circulation 108(3):367–372CrossRef Stevenson LW (2003) Clinical Use of Inotropic Therapy for Heart Failure: Looking Backward or Forward? Part I: Inotropic Infusions During Hospitalization. Circulation 108(3):367–372CrossRef

go back to reference Maisel A, Mueller C, Adams K Jr, Anker SD, Aspromonte N, Cleland JG, Cohen-Solal A, Dahlstrom U, DeMaria A, Di Somma S, Filippatos GS, Fonarow GC, Jourdain P, Komajda M, Liu PP, McDonagh T, McDonald K, Mebazaa A, Nieminen MS, Peacock WF, Tubaro M, Valle R, Vanderhyden M, Yancy CW, Zannad F, Braunwald E (2008) State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 10(9):824–839CrossRef Maisel A, Mueller C, Adams K Jr, Anker SD, Aspromonte N, Cleland JG, Cohen-Solal A, Dahlstrom U, DeMaria A, Di Somma S, Filippatos GS, Fonarow GC, Jourdain P, Komajda M, Liu PP, McDonagh T, McDonald K, Mebazaa A, Nieminen MS, Peacock WF, Tubaro M, Valle R, Vanderhyden M, Yancy CW, Zannad F, Braunwald E (2008) State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 10(9):824–839CrossRef

go back to reference Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, Lip GY, Coats AJ, Andersson B, Kirchhof P, von Lueder TG, Wedel H, Rosano G, Shibata MC, Rigby A, Flather MD (2014) Beta-Blockers in Heart Failure Collaborative G. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 384(9961):2235–2243CrossRef Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, Lip GY, Coats AJ, Andersson B, Kirchhof P, von Lueder TG, Wedel H, Rosano G, Shibata MC, Rigby A, Flather MD (2014) Beta-Blockers in Heart Failure Collaborative G. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 384(9961):2235–2243CrossRef

go back to reference Eid PS, Ibrahim DA, Zayan AH, Abdelrahman MM, Shehata MAA, Kandil H, Abouibrahim MA, Duy LM, Shinkar A, Elfaituri MK, Minh LHN, Fahmy MM, Tam DNH, Vuong NL, Shah J, Do VBD, Hirayama K, Huy NT (2020) Comparative effects of furosemide and other diuretics in the treatment of heart failure: a systematic review and combined meta-analysis of randomized controlled trials [published online ahead of print, Aug 11]. Heart Fail Rev https://doi.org/10.1007/s10741-020-10003-7 Eid PS, Ibrahim DA, Zayan AH, Abdelrahman MM, Shehata MAA, Kandil H, Abouibrahim MA, Duy LM, Shinkar A, Elfaituri MK, Minh LHN, Fahmy MM, Tam DNH, Vuong NL, Shah J, Do VBD, Hirayama K, Huy NT (2020) Comparative effects of furosemide and other diuretics in the treatment of heart failure: a systematic review and combined meta-analysis of randomized controlled trials [published online ahead of print, Aug 11]. Heart Fail Rev https://​doi.​org/​10.​1007/​s10741-020-10003-7

go back to reference Böhm M, Young R, Jhund PS, Solomon S, Gong J, Lefkowitz M, Rizkala A, Rouleau J, Shi V, Swedberg K, Zile M, Packer M, McMurray J (2017) Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J 38(15):1132–1143. https://doi.org/10.1093/eurheartj/ehw570CrossRefPubMedPubMedCentral Böhm M, Young R, Jhund PS, Solomon S, Gong J, Lefkowitz M, Rizkala A, Rouleau J, Shi V, Swedberg K, Zile M, Packer M, McMurray J (2017) Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J 38(15):1132–1143. https://​doi.​org/​10.​1093/​eurheartj/​ehw570CrossRefPubMedPubMedCentral

go back to reference McAlister F, Youngson E, Kaul P, Ezekowitz J (2016) Early Follow-Up After a Heart Failure Exacerbation. The Importance of Continuity. Circ Heart Fail 9(9):e003194. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003194 McAlister F, Youngson E, Kaul P, Ezekowitz J (2016) Early Follow-Up After a Heart Failure Exacerbation. The Importance of Continuity. Circ Heart Fail 9(9):e003194. https://​doi.​org/​10.​1161/​CIRCHEARTFAILURE​.​116.​003194